M&A Deal Summary

Vaccitech Acquires Avidea Technologies

On December 13, 2021, Vaccitech acquired life science company Avidea Technologies for 40M USD

Acquisition Highlights
  • This is Vaccitech’s 1st transaction in the Life Science sector.
  • This is Vaccitech’s largest (disclosed) transaction.
  • This is Vaccitech’s 1st transaction in the United States.
  • This is Vaccitech’s 1st transaction in Maryland.

M&A Deal Summary
Date 2021-12-13
Target Avidea Technologies
Sector Life Science
Buyer(s) Vaccitech
Deal Type Add-on Acquisition
Deal Value 40M USD

Target

Avidea Technologies

Baltimore, Maryland, United States
Avidea Technologies is a biotechnology company that is advancing the next generation of safer and more effective T cell immunotherapies for treating cancer, infections, and autoimmune diseases. Avidea Technologies is based in Baltimore, Maryland.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vaccitech

Oxford, United Kingdom
Category Company
Founded 2016
Sector Life Science
Employees48
Revenue 5M USD (2020)
DESCRIPTION

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases and cancer. Vaccitech was founded in 2016 and is based in Oxford, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Maryland) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal